Leflunomide-induced Toxic Epidermal Necrolysis in a Patient with Rheumatoid Arthritis
Journal of Rheumatic Diseases
;
: 326-330, 2014.
Article
in English
| WPRIM
| ID: wpr-54157
ABSTRACT
Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998 and has been available in Korea since 2003. Allergic cutaneous reactions (rash, purpura) are common (<10%) side effects of leflunomide, but severe cases such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are rarely reported. There has not been a report of SJS or TEN induced by leflunomide in Korea. Here we report a case of leflunomide-induced TEN in a patient with rheumatoid arthritis. Leflunomide was discontinued, and the TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved over four weeks with residual post-inflammatory hyperpigmentation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Rheumatoid
/
Skin
/
Immunoglobulins
/
Methylprednisolone
/
Cholestyramine Resin
/
Stevens-Johnson Syndrome
/
Hyperpigmentation
/
Korea
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Rheumatic Diseases
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS